First Light Asset Management LLC Sells 161,683 Shares of AtriCure, Inc. $ATRC

First Light Asset Management LLC cut its holdings in AtriCure, Inc. (NASDAQ:ATRC) by 22.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 567,838 shares of the medical device company’s stock after selling 161,683 shares during the quarter. AtriCure makes up about 1.0% of First Light Asset Management LLC’s holdings, making the stock its 28th biggest holding. First Light Asset Management LLC owned 1.12% of AtriCure worth $15,888,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Geneos Wealth Management Inc. purchased a new stake in AtriCure in the second quarter worth about $37,000. Harbor Investment Advisory LLC purchased a new position in shares of AtriCure during the second quarter valued at approximately $40,000. Allworth Financial LP purchased a new position in shares of AtriCure during the second quarter valued at approximately $43,000. Integrated Wealth Concepts LLC bought a new stake in shares of AtriCure in the 2nd quarter worth approximately $46,000. Finally, Smartleaf Asset Management LLC boosted its position in shares of AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares in the last quarter. 99.11% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on ATRC. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Weiss Ratings raised AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. BTIG Research increased their target price on AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, August 24th. UBS Group reduced their price target on AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Finally, Piper Sandler lifted their price target on AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, AtriCure currently has an average rating of “Moderate Buy” and an average price target of $52.00.

Insider Buying and Selling

In other AtriCure news, insider Salvatore Privitera sold 7,763 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $52.50, for a total value of $407,557.50. Following the completion of the transaction, the insider owned 150,921 shares of the company’s stock, valued at approximately $7,923,352.50. The trade was a 4.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Justin Noznesky sold 6,182 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total transaction of $239,861.60. Following the transaction, the insider owned 100,219 shares in the company, valued at $3,888,497.20. This represents a 5.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 61,379 shares of company stock worth $2,557,552 in the last three months. 4.00% of the stock is currently owned by company insiders.

AtriCure Stock Performance

ATRC stock opened at $53.03 on Thursday. The stock’s 50 day simple moving average is $41.54 and its 200 day simple moving average is $33.26. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. AtriCure, Inc. has a 12-month low of $25.36 and a 12-month high of $55.72. The stock has a market capitalization of $2.70 billion, a PE ratio of 252.54 and a beta of 1.26.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The business had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. During the same quarter last year, the company earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, research analysts forecast that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.